Study of WGb-0302 for multiple myeloma that returned or didn't respond to treatment
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new therapy called WGb-0302 for people with multiple myeloma that has come back or is not responding to other treatments. It aims to see if this therapy can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your doctor expects you to live more than 12 weeks.
- You have multiple myeloma that shows a protein called BCMA on the cancer cells.
- Your cancer is measurable (can be tracked with tests).
- You are in good enough health to do daily activities (ECOG score 0 or 1).
- You agree to use reliable birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment, WGb-0301, for people with B-cell lymphoma or leukemia that has come back or not responded to other therapies. It aims to see if this therapy can help when standard options are no longer working.
This trial tests a new drug called CM336 for people with multiple myeloma that has come back or stopped responding to at least two previous treatments. It aims to see if CM336 can help control the disease.
This trial tests an investigational drug called IBI3003 in people with multiple myeloma that has come back or hasn't responded to previous treatments. The goal is to see if it is safe and effective.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This trial tests a new injectable treatment for people with multiple myeloma that has come back or not responded to previous therapies. It aims to see if the drug is safe and effective.
This study tests a new drug called IBI3003 in people whose multiple myeloma (a blood cancer) has come back or stopped responding to previous treatments. The goal is to see if this drug can shrink the cancer and help patients live longer.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.